OPKO Health Inc
Cerrado
SectorSanidad
1.55 -0.64
Resumen
Variación precio
24h
Mínimo
1.55
Máximo
1.56
Ingresos | 46M -8.4M |
|---|---|
Ventas | 39M 164M |
BPA | -0.01 |
Margen de beneficios | -5.145 |
Empleados | 2,275 |
EBITDA | 40M 12M |
Próximas Ganancias | 28 oct 2026 |
|---|
Capitalización Mercado | 318M 1.2B |
|---|---|
Apertura anterior | 2.19 |
Cierre anterior | 1.55 |
Noticias sobre sentimiento de mercado
By Acuity
31%
69%
60 / 339 Clasificación en Healthcare
OPKO Health Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
OPKO Health Inc previsión
Sentimiento
By Acuity
60 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de OPKO Health Inc
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.
